Topic: How To Invest

Hi Pat: Can you give me your view on Merck & Co., or perhaps an alternative to this company? Thanks.

Article Excerpt

Merck & Co., $38.81, symbol MRK on New York (Shares outstanding: 3.0 billion; Market cap: $116.4 billion; www.merck.com), is a global health care company providing prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. Merck’s top-selling drugs include Singulair (for treating respiratory illnesses), Remicade (arthritis), Zetia and Vytorin (high cholesterol), and Januvia (diabetes). In the three months ended December 31, 2011, Merck’s revenue rose 1.7%, to $12.3 billion from $12.1 billion a year earlier. Excluding one-time items, earnings rose 8.1%, to $3.0 billion from $2.8 billion. Earnings per share rose 10.2%, to $0.97 from $0.88, on fewer shares outstanding. Merck holds cash of $15.0 billion, or $5.00 a share. Its long-term debt of $15.5 billion is a low 13.3% of its market cap. The company should report higher profits in 2012, even though its top-selling drug, Singulair, is coming off patent in August. (Singulair supplies 11% of Merck’s overall revenue.) That means this product will face competition from cheaper, generic versions…